A new med is called a non-stimulant. The label says stimulant. The trials say less.
Psychology Today
Despite being marketed as a first-in-class triple reuptake inhibitor, centanafadine is pharmacologically a norepinephrine-dominant drug with significantly lower potency for dopamine and serotonin transporters. Clinical trials show its efficacy is modest, with effect sizes roughly half that of amphetamines and comparable to other non-stimulant options like atomoxetine. Consequently, the medication's stimulant label and claims of rapid onset require careful interpretation due to inconsistent results across adult populations and symptom types.
All articles from 9 August 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.